Chronic Back Pain Drug Advances
Mesoblast Reaches 300-Patient Milestone in Key Back Pain Trial, Citing $10 Billion Revenue Potential
Key Points
The MSB-DR004 trial's primary endpoint is powered to show a significant difference in reduction of low back pain at 12 months between rexlemestrocel-L and sham controls, with secondary endpoints including improvements in function, quality of life, and cessation of pain medications including opioids.
Rexlemestrocel-L is described as a second-generation allogeneic product that is STRO3-immunoselected and produced industrially, delivered via a single intra-discal injection in the trial.
Rexlemestrocel-L has FDA Regenerative Medicine Advanced Therapy (RMAT) designation, giving eligibility for priority-like review and potential rolling review of a future BLA after filing.
Industry coverage notes discogenic back pain can account for around half of US prescription opioid use, highlighting the potential market impact if rexlemestrocel-L proves effective.
Mesoblast has hit a key milestone in its pivotal Phase 3 trial for chronic low back pain, treating at least 300 patients with its cell therapy rexlemestrocel-L, according to Kalkine. The company says this makes the study statistically powerful enough to detect a real treatment effect — a major de-risking step on the road to potential approval.
Top-line results are expected in mid-2027. If successful, the treatment could generate more than US$10 billion in annual peak revenue at just single-digit market penetration, according to Stocks Down Under.
What the 300-Patient Mark Actually Means
The MSB-DR004 trial is a randomised controlled study pitting rexlemestrocel-L against a sham procedure. Hitting 300 treated patients means the trial is now fully powered to detect a statistically significant difference in pain reduction at 12 months, ShareCafe reported. The last enrolled patient finishes their 12-month follow-up in mid-2027, triggering the data read-out.
Management called the milestone a meaningful de-risking event. It enables a faster path to a regulatory filing if results hold up. Commercial manufacturing is already running in parallel to cut the lag between a positive result and a potential product launch, according to Finn News Network.
A Single Injection Targeting Disc-Driven Pain
Rexlemestrocel-L is an allogeneic cell therapy — meaning it is made from donor cells, not the patient's own. It is described as a second-generation product that is STRO3-immunoselected, which means cells are screened and selected for higher potency. Patients receive a single injection directly into the affected disc, according to Market Screener.
The trial's primary goal is to show a significant drop in low back pain scores at 12 months. Secondary goals include better physical function, improved quality of life, and getting patients off pain medications — including opioids. Discogenic back pain is thought to drive around half of all US prescription opioid use, Stocks Down Under noted.
FDA's RMAT Tag Clears the Way for Faster Review
Rexlemestrocel-L holds FDA Regenerative Medicine Advanced Therapy designation — known as RMAT. This status gives Mesoblast access to priority-like review and potentially a rolling review of its future Biologics License Application. That means the FDA can begin reviewing sections of the filing before the full application is complete, speeding up the process, according to Kalkine.
RMAT designation is reserved for regenerative therapies targeting serious conditions. It is a stronger form of support than standard fast-track status. Mesoblast says this aligns with its goal of swift regulatory progression if the Phase 3 data confirms prior efficacy signals.
A US$10 Billion Prize in a Massive Unmet Market
More than 7 million US patients are estimated to suffer from chronic low back pain linked to degenerative disc disease. At single-digit market penetration, Mesoblast sees peak annual revenue exceeding US$10 billion — a figure that would dwarf the company's other assets, according to Stocks Down Under. For context, Mesoblast's approved pediatric product Ryoncil targets a far smaller patient pool.
The Phase 3 trial is confirmatory, not exploratory. Earlier studies already produced positive signals of durable pain reduction. Finn News Network reported that Mesoblast designed MSB-DR004 specifically to replicate those results at a scale acceptable to regulators — making the 300-patient milestone a genuine turning point for the program.
Sentiment
Mostly PositivePublishers
18
Articles
32
Reach
50
